National Institute of Neurological Disorders and Stroke, Interagency Pain Research Coordinating Committee Call for Committee Membership Nominations, 65695 [2018-27737]
Download as PDF
<![CDATA[
Federal Register / Vol. 83, No. 245 / Friday, December 21, 2018 / Notices
amozie on DSK3GDR082PROD with NOTICES1
licensed to the government of the
United States of America.
The prospective exclusive license
territory may be where patent
applications are filed and the field of
use may be limited to ‘‘Multifunctional
RNA nanoparticle functionalized by
RNA toeholds as a drug delivery agent
carrying gene therapeutic or geneediting cargo and/or aptamers’’.
Additional licensable fields of use are
available (e.g. functionalized with
proteins or imaging agent).
The technologies disclose RNA and
RNA/DNA (‘‘R/DNA’’) nanoparticles in
the form of a hexameric ring that have
arms attached off the sides of the ring
in which the arms could be siRNAs,
RNA aptamers, fluorescent dyes,
imaging agents and/or proteins in
various combinations and use of singlestranded RNA toeholds of lengths of 12
nucleotides or less contained in nucleic
acid-based nanoparticles, such as the
nanoring, which trigger the association
of these nanoparticles and activates
multiple functionalities such as gene
silencing and/or cell-specific targeting.
This notice is made in accordance with
35 U.S.C. 209 and 37 CFR part 404. The
prospective exclusive license will be
royalty bearing, and the prospective
exclusive license may be granted unless
within fifteen (15) days from the date of
this published notice, the National
Cancer Institute receives written
evidence and argument that establishes
that the grant of the license would not
be consistent with the requirements of
35 U.S.C. 209 and 37 CFR part 404.
In response to this Notice, the public
may file comments or objections.
Comments and objections, other than
those in the form of a license
application, will not be treated
confidentially, and may be made
publicly available.
License applications submitted in
response to this Notice will be
presumed to contain business
confidential information and any release
of information in these license
applications will be made only as
required and upon a request under the
Freedom of Information Act, 5 U.S.C.
552.
Dated; December 11, 2018.
Richard U. Rodriguez,
Associate Director, Technology Transfer
Center, National Cancer Institute.
[FR Doc. 2018–27671 Filed 12–20–18; 8:45 am]
BILLING CODE 4140–01–P
VerDate Sep<11>2014
00:00 Dec 21, 2018
Jkt 247001
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Institute of Neurological
Disorders and Stroke, Interagency Pain
Research Coordinating Committee Call
for Committee Membership
Nominations
AGENCY:
National Institutes of Health,
HHS.
ACTION:
Notice.
The Department of Health and
Human Services (HHS) (Department)
has created the Interagency Pain
Research Coordinating Committee
(IPRCC) and is seeking nominations for
this committee.
DATES: Nominations are due by 5 p.m.
on January 25, 2019.
ADDRESSES: Nominations must be
submitted through the webform on the
IPRCC website: https://iprcc.nih.gov/
About/Membership-AgencyRepresentation/Nomination-Form.
FOR FURTHER INFORMATION CONTACT:
Linda Porter at 301–451–4460 or email
at porterl@ninds.nih.gov.
SUPPLEMENTARY INFORMATION: As
specified in Public Law 111–148
(‘‘Patient Protection and Affordable Care
Act’’) and amended in H.R. 6, (‘‘Support
for Patients and Communities Act’’) the
Committee will:
(A) Develop a summary of advances
in pain care research supported or
conducted by the Federal agencies
relevant to the diagnosis, prevention,
treatment, and management of pain and
diseases and disorders associated with
pain, including information on best
practices for the utilization of nonpharmacologic treatments, nonaddictive medical products, and other
drugs or devices approved or cleared by
the Food and Drug Administration;
(B) identify critical gaps in basic and
clinical research on
(i) the symptoms and causes of pain,
including the identification of relevant
biomarkers and screening models and
the epidemiology of acute and chronic
pain;
(ii) the diagnosis, prevention,
treatment, and management of acute and
chronic pain, including with respect to
non-pharmacologic treatments, nonaddictive medical products, and other
drugs or devices approved or cleared by
the Food and Drug Administration; and
(iii) risk factors for, and early warning
signs of, substance use disorders in
populations with acute and chronic
pain;
(C) make recommendations to the
Director of NIH
SUMMARY:
PO 00000
Frm 00074
Fmt 4703
Sfmt 9990
65695
(i) to ensure that the activities of the
National Institutes of Health and other
Federal agencies are free of unnecessary
duplication of effort;
(ii) on how best to disseminate
information on pain care and
epidemiological data related to acute
and chronic pain; and
(iii) on how to expand partnerships
between public entities and private
entities to expand collaborative, crosscutting research.
Membership on the committee will
include six (6) non-Federal members
from among scientists, physicians, and
other health professionals and six (6)
non-Federal members of the general
public who are representatives of
leading research, advocacy, and service
organizations for individuals with painrelated conditions. Members will serve
overlapping three year terms. It is
anticipated that the committee will meet
at least once a year.
The Department strives to ensure that
the membership of HHS Federal
advisory committees is fairly balanced
in terms of points of view represented
and the committee’s function. Every
effort is made to ensure that the views
of diverse ethnic and racial groups and
people with disabilities are represented
on HHS Federal advisory committees,
and the Department therefore,
encourages nominations of qualified
candidates from these groups. The
Department also encourages geographic
diversity in the composition of the
Committee. Appointment to this
Committee shall be made without
discrimination on the basis of age, race,
ethnicity, gender, sexual orientation,
disability, and cultural, religious, or
socioeconomic status.
The Department is soliciting
nominations for 5 non-federal members
from among scientists, physicians, and
other health professionals and for 3 nonfederal members of the general public
who represent a leading research,
advocacy, or service organization for
people with pain-related conditions.
These candidates will be considered to
fill positions opened through
completion of current member terms.
Nominations are due by 5 p.m. on
January 25, 2019, using the IPRCC
nomination webform: https://
iprcc.nih.gov/About/MembershipAgency-Representation/NominationForm.
Dated: December 11, 2018.
Walter J. Koroshetz,
Director, National Institute of Neurological
Disorders and Stroke, National Institutes of
Health.
[FR Doc. 2018–27737 Filed 12–20–18; 8:45 am]
BILLING CODE 4140–01–P
E:\FR\FM\21DEN1.SGM
21DEN1
]]>Agencies
[Federal Register Volume 83, Number 245 (Friday, December 21, 2018)]
[Notices]
[Page 65695]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2018-27737]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
National Institute of Neurological Disorders and Stroke,
Interagency Pain Research Coordinating Committee Call for Committee
Membership Nominations
AGENCY: National Institutes of Health, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: The Department of Health and Human Services (HHS) (Department)
has created the Interagency Pain Research Coordinating Committee
(IPRCC) and is seeking nominations for this committee.
DATES: Nominations are due by 5 p.m. on January 25, 2019.
ADDRESSES: Nominations must be submitted through the webform on the
IPRCC website: https://iprcc.nih.gov/About/Membership-Agency-Representation/Nomination-Form.
FOR FURTHER INFORMATION CONTACT: Linda Porter at 301-451-4460 or email
at porterl@ninds.nih.gov.
SUPPLEMENTARY INFORMATION: As specified in Public Law 111-148
(``Patient Protection and Affordable Care Act'') and amended in H.R. 6,
(``Support for Patients and Communities Act'') the Committee will:
(A) Develop a summary of advances in pain care research supported
or conducted by the Federal agencies relevant to the diagnosis,
prevention, treatment, and management of pain and diseases and
disorders associated with pain, including information on best practices
for the utilization of non-pharmacologic treatments, non-addictive
medical products, and other drugs or devices approved or cleared by the
Food and Drug Administration;
(B) identify critical gaps in basic and clinical research on
(i) the symptoms and causes of pain, including the identification
of relevant biomarkers and screening models and the epidemiology of
acute and chronic pain;
(ii) the diagnosis, prevention, treatment, and management of acute
and chronic pain, including with respect to non-pharmacologic
treatments, non-addictive medical products, and other drugs or devices
approved or cleared by the Food and Drug Administration; and
(iii) risk factors for, and early warning signs of, substance use
disorders in populations with acute and chronic pain;
(C) make recommendations to the Director of NIH
(i) to ensure that the activities of the National Institutes of
Health and other Federal agencies are free of unnecessary duplication
of effort;
(ii) on how best to disseminate information on pain care and
epidemiological data related to acute and chronic pain; and
(iii) on how to expand partnerships between public entities and
private entities to expand collaborative, cross-cutting research.
Membership on the committee will include six (6) non-Federal
members from among scientists, physicians, and other health
professionals and six (6) non-Federal members of the general public who
are representatives of leading research, advocacy, and service
organizations for individuals with pain-related conditions. Members
will serve overlapping three year terms. It is anticipated that the
committee will meet at least once a year.
The Department strives to ensure that the membership of HHS Federal
advisory committees is fairly balanced in terms of points of view
represented and the committee's function. Every effort is made to
ensure that the views of diverse ethnic and racial groups and people
with disabilities are represented on HHS Federal advisory committees,
and the Department therefore, encourages nominations of qualified
candidates from these groups. The Department also encourages geographic
diversity in the composition of the Committee. Appointment to this
Committee shall be made without discrimination on the basis of age,
race, ethnicity, gender, sexual orientation, disability, and cultural,
religious, or socioeconomic status.
The Department is soliciting nominations for 5 non-federal members
from among scientists, physicians, and other health professionals and
for 3 non-federal members of the general public who represent a leading
research, advocacy, or service organization for people with pain-
related conditions. These candidates will be considered to fill
positions opened through completion of current member terms.
Nominations are due by 5 p.m. on January 25, 2019, using the IPRCC
nomination webform: https://iprcc.nih.gov/About/Membership-Agency-Representation/Nomination-Form.
Dated: December 11, 2018.
Walter J. Koroshetz,
Director, National Institute of Neurological Disorders and Stroke,
National Institutes of Health.
[FR Doc. 2018-27737 Filed 12-20-18; 8:45 am]
BILLING CODE 4140-01-P
